title: Effect of intravesical glycosaminoglycan substitution therapy on bladder pain syndrome/interstitial cystitis, bladder capacity and potassium sensitivity.
abstract: OBJECTIVE
  To evaluate changes in bladder capacity and potassium sensitivity after glycosaminoglycan (GAG) substitution therapy.
  
  
  METHODS
  The study population comprised two groups of female patients with bladder pain syndrome/interstitial cystitis (BPS/IC): responders (those with symptom improvement) and non-responders (those without symptom improvement) after a 10-week period of intravesical, episodic, weekly, GAG substitution therapy. A total of 27 volunteers with increased pre-therapeutic potassium sensitivity were enrolled in the study and re-evaluated using the modified comparative potassium test (maximal bladder capacity with a saline solution versus a 0.2 M KCl solution) following intravesical GAG substitution therapy.
  
  
  RESULTS
  In the 13 responders, the average maximal bladder capacity increased by 17% with the saline solution and by 101.5% with the 0.2 M KCl solution. In the 14 non-responders, post-therapeutic average maximal bladder capacity was decreased by 35% with the saline solution and remained relatively unchanged after instillation with a 0.2 M KCl solution.
  
  
  CONCLUSIONS
  These data demonstrate that in patients who respond symptomatically to intravesical GAG substitution therapy, cystometric bladder capacity is increased, whereas non-responders experience a decrease in bladder capacity.
authors.affiliation: Department of Urology, Municipal Hospital Hietzing, Vienna, Austria. lukas.daha@wienkav.at
authors.forename: Lukas K
authors.initials: LK
authors.lastname: Daha
authors.forename: Claus R
authors.initials: CR
authors.lastname: Riedl
authors.forename: Dara
authors.initials: D
authors.lastname: Lazar
authors.forename: Reiner
authors.initials: R
authors.lastname: Simak
authors.forename: Heinz
authors.initials: H
authors.lastname: Pflüger
mesh_terms: D000283:Administration, Intravesical; D000328:Adult; D000368:Aged; D018856:Cystitis, Interstitial / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D006025:Glycosaminoglycans / Q000008:administration & dosage* / Q000627:therapeutic use*; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D010426:Pentosan Sulfuric Polyester / Q000008:administration & dosage / Q000627:therapeutic use; D011189:Potassium Chloride / Q000494:pharmacology*; D011446:Prospective Studies; D001743:Urinary Bladder / Q000187:drug effects / Q000473:pathology* / Q000503:physiopathology
chemical_list: D006025:Glycosaminoglycans; D010426:Pentosan Sulfuric Polyester; D011189:Potassium Chloride; D006820:Hyaluronic Acid